Skip to main content
main-content

12.04.2015 | Original Article | Ausgabe 5/2016

Heart and Vessels 5/2016

Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial

Zeitschrift:
Heart and Vessels > Ausgabe 5/2016
Autoren:
Francesco Burzotta, Marta Francesca Brancati, Carlo Trani, Giancarlo Pirozzolo, Gianluigi De Maria, Antonio Maria Leone, Giampaolo Niccoli, Italo Porto, Francesco Prati, Filippo Crea
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00380-015-0671-3) contains supplementary material, which is available to authorized users.

Abstract

The efficacy of DEB in modifying the high restenosis risk associated with BMS implantation is doubtful. Optical coherence tomography (OCT) may allow precise assessment of neointimal formation after stent implantation. We performed a single-center, prospective, 1:2 randomized trial comparing BMS implantation alone (BMS group) vs. additional DEB (DEB group). DEB patients were further randomized 1:1 to DEB before stenting (pre-DEB group), or after stenting (post-DEB group). Primary endpoint was OCT-assessed neointimal hyperplasia (expressed both as mean in-stent neointimal area and as percentage obstruction of the mean stent area) at 6 months. Secondary endpoints were the percentage of uncovered and malapposed stent struts. Thirty patients were enrolled and randomized to BMS (n = 10), pre-DEB (n = 10), post-DEB (n = 10). At 6-month OCT follow-up, DEB significantly reduced neointimal area compared with BMS: mean neointimal area 2.01 ± 0.89 vs. 3.03 ± 1.07 mm2 (p = 0.02), percentage area obstruction 24.56 ± 12.50 vs. 37.51 ± 12.26 % (p = 0.02). The percentage of uncovered and malapposed stent struts did not differ significantly between BMS and DEB. In the comparison between pre-DEB and post-DEB, no significant difference was observed for both primary and secondary endpoints. In de novo coronary lesions treated with BMS, DEB use could be associated with a mild reduction in neointimal hyperplasia at 6 months; this effect could be unrelated to the timing of DEB dilation (pre- or post-stenting).
Clinical Trial Registration Information: http://​www.​clinicaltrials.​gov. Identifier: NCT01057563.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
Supplementary material 1 (DOC 38 kb)
380_2015_671_MOESM1_ESM.doc
Supplementary material 2 (DOC 40 kb)
380_2015_671_MOESM2_ESM.doc
Supplementary material 3 (DOC 34 kb)
380_2015_671_MOESM3_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2016

Heart and Vessels 5/2016 Zur Ausgabe


 

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise